
Ocugen, Inc. Common Stock
OCGN
OCGN: Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
moreShow OCGN Financials
Recent trades of OCGN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OCGN's directors and management
Government lobbying spending instances
-
$30,000 Jul 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$30,000 Jul 19, 2023 Issue: Health Issues
-
$20,000 Apr 20, 2023 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
-
$30,000 Apr 18, 2023 Issue: Health Issues
-
$105,000 Feb 23, 2023 Issue: Health Issues
-
$10,000 Jan 20, 2023 Issue: Health Issues
-
$105,000 Nov 16, 2022 Issue: Health Issues
-
$105,000 Aug 08, 2022 Issue: Health Issues
-
$20,000 Jul 20, 2022 Issue: Pharmacy
-
$105,000 Jun 09, 2022 Issue: Health Issues
-
$130,000 Apr 20, 2022 Issue: Pharmacy
-
$60,000 Jan 20, 2022 Issue: Health Issues
-
$130,000 Jan 20, 2022 Issue: Pharmacy
-
$60,000 Oct 21, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2021 Issue: Pharmacy
-
$60,000 Jul 19, 2021 Issue: Health Issues
-
$60,000 Jul 19, 2021 Issue: Health Issues
New patents grants
-
Patent Title: Method for use of a double-structured tissue implant for treatment of tissue May. 16, 2023
-
Patent Title: Cell and tissue culture container Jan. 17, 2023
-
Patent Title: Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders Aug. 25, 2020
-
Patent Title: Ophthalmic compositions and methods of use Feb. 11, 2020
-
Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Jan. 30, 2018
-
Patent Title: Methods and compositions for treating dry eye disease and other eye disorders Mar. 21, 2017
Federal grants, loans, and purchases
Followers on OCGN's company Twitter account
Number of mentions of OCGN in WallStreetBets Daily Discussion
Recent insights relating to OCGN
Recent picks made for OCGN stock on CNBC
ETFs with the largest estimated holdings in OCGN
Flights by private jets registered to OCGN